Why the study?
Does low molecular weight heparin safely prevent and treat thromboembolism in pregnant women?
Does low molecular weight heparin safely prevent and treat thromboembolism in pregnant women?
Low molecular weight heparin appears to be a safe and effective alternative to standard heparin for thromboembolism prophylaxis and treatment during pregnancy.
Answers are grounded in this paper and cite their sources.
May support LMWH consideration in pregnancy; leaves open need for prospective validation.
Low molecular weight heparin (LMWH) preserves the antithrombotic action but not the anticoagulant activity of heparin. LMWH is safe, does not cross the placenta and is administered as a single daily injection. We report our experience with 6 pregnant women given LMWH for treatment or prophylaxis of thromboembolism. The drug was successfully given to 5 women for periods of 6 weeks--6 months and no thromboembolic complications occurred during pregnancy or pueperium. There were no hemorrhagic complications and no excessive bleeding was observed during delivery. The sixth patient relapsed after 6 weeks of therapy. This patient also showed resistance to standard heparin administered intravenously at a very high dose. LMWH should be considered an alternative to standard heparin in pregnant women requiring antithrombotic prophylaxis and therapy.
No takes yet. Share an insight, caveat, or question.
Gillis et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: